Detail akcie Sopharma AD Sofia, Ordinary, MiFID Eligible Security, Warsaw Stock Exchange online

Business Summary: Sopharma AD, formerly Sopharma AD Sofia, is a Bulgaria-based company engaged in the generic pharmaceutical industry. The Company specializes in the production and trade of medical substances and finished drug forms, as well as research and development in the field of medical products. Through the ampoule plant, tablet plant and the plant in Vrabevo it produces medicines, such as analgesics, antipyretics, cardiovascular medicines as well as drugs for respiratory disease treatment, among others. The Company offers its products under the brand Tribestan, Nivalin and Tabex, among others. In addition, it specializes in the gamma-sterilization of medical materials. It is the parent company of Sopharma Group and operates domestically and abroad in such countries as Russian Federation, Poland, Ukraine, Serbia, the United States and the United Kingdom, among others.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Sopharma AD revenues increased 9% to BGN1.01B. Net income decreased 28% to BGN45.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was offset by Purchase Value of Sold Assets increase of 12% to BGN749.8M (expense), Employee Related Expenses increase of 18% to BGN84.1M (expense).